AstraZeneca's Brilique Cleared In NICE's Initial Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s cost regulator, NICE, clears AstraZeneca's antiplatelet drug ticagrelor for use in the National Health Service in a preliminary assessment.
You may also be interested in...
Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.
Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.
AstraZeneca Gives FDA More Data On Brilinta Interaction With High-Dose Aspirin
In replying to FDA's December "complete response," company reaffirms its view that U.S. efficacy in the pivotal PLATO study was undercut by high doses of concomitant aspirin.